Fig. 1

The expression of EPN3 is significantly increased and associated with poor prognosis in patients with NSCLC. A TCGA database analysis of EPN1, EPN2 and EPN3 expression levels in LUAD, LUSC and normal tissues. B GEO database analysis of EPN3 expression levels in tumour and paracancerous tissue. C Kaplan–Meier survival analysis of NSCLC patients stratified according to the EPN3 expression level. D TCGA database analysis of EPN3 expression levels in BRCA, COAD and normal tissues. E mRNA expression level of EPN3 in 31 paired NSCLC tissues and paracancerous tissues. F Protein expression level of EPN3 in paracancerous tissue (N = normal) and lung cancer tissue (T = tumour). G mRNA expression level of EPN3 in 16HBE, A549, H1975, H1703 and H1299 cells (n = 4). H Protein expression level of EPN3 in 16HBE, A549, H1975, H1703 and H1299 cells (n = 3). The protein expression levels were normalized to those of β-tubulin in each sample. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. control group